Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Literature Review on Janus Kinase (Jak) Inhibitors for the Treatment of Immunobullous Disorders Publisher Pubmed



Kalantari Y1, 2 ; Sadeghi S3, 4 ; Asadi D1 ; Goodarzi A4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pediatrics, Division of Dermatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
  4. 4. Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: International Immunopharmacology Published:2022


Abstract

Janus kinases (JAKs) are a group of intracytoplasmic tyrosine kinase proteins that bind to the cytoplasmic part of the transmembrane cytokine receptors and regulate signaling. The pathophysiology of various autoimmune and autoinflammatory conditions relies on JAK/STAT signaling and therefore, the inhibition of JAK/STAT pathways can be a promising treatment for such diseases, especially inflammatory skin conditions. The current study aimed to evaluate the efficacy of JAK inhibitors in the treatment of immunobullous diseases, including pemphigus, pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa. The databases used to identify the studies were Web of Science, Scopus, and PubMed/Medline for studies published until 2/3/2022. The current review suggests that JAK inhibitors may be revolutionary for the future treatments of dermatologic conditions, especially autoimmune bullous disease. Results also indicated the effectiveness of JAK inhibitors for the treatment of immunobullous diseases. © 2022
Related Docs
1. Janus-Kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature, Journal of Pediatrics Review (2023)
2. Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate, Pharmaceutical Sciences (2023)
3. Jak Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? a Systematic Review of the Published Literature, Cancers (2024)
4. Jak Inhibitors in the Treatment of Lichen Planopilaris, Skin Appendage Disorders (2024)
5. Sars-Cov-2 Vaccination and Practical Points in Psoriasis Patients: A Narrative Review, Dermatologic Therapy (2022)
Experts (# of related papers)
View all Related Experts
Alireza Firooz (1)
Zeinab Aryanian (1)